StemCells Inc (STEM.OQ)
24 Jun 2016
StemCells Inc said it would wind down operations after the company terminated a mid-stage trial testing its therapy in spinal cord injury, sending its shares plummeting 85 percent.
* Shares plunge 85 pct (Adds analyst comment, details; updates shares)
May 31 StemCells Inc said on Tuesday it had terminated a mid-stage trial in spinal cord injury and that its board had decided to wind down the company.
* Files for rights offering for up to $30 million - SEC filing Source text for Eikon: Further company coverage:
* Trading common stock on Nasdaq Capital Market will continue, on a split-adjusted basis, on may 9, 2016 Further company coverage: (Bengaluru Newsroom; +1 646 223 8780; )
* Trading of common stock on Nasdaq capital market will continue, on a split-adjusted basis, on May 9, 2016 Source text for Eikon: Further company coverage:
* Stemcells inc says presents interim results from its phase ii pathway study in chronic cervical spinal cord injury
* Stemcells, inc. Reports fourth quarter and full year 2015 financial results and provides business update
|Novartis AG (NOVN.S)||CHF75.75||-1.20|
|Pfizer Inc. (PFE.N)||$33.97||-0.62|
|Roche Holding Ltd. (ROG.S)||CHF241.00||-5.50|
|Roche Holding Ltd. (RO.S)||CHF246.20||-3.30|
|Merck & Co., Inc. (MRK.N)||$55.88||-1.80|
|Sanofi SA (SASY.PA)||€69.37||-2.63|
|Abbott Laboratories (ABT.N)||$37.91||-1.72|
|Amgen, Inc. (AMGN.OQ)||$146.45||-5.82|
|Merck KGaA (MRCG.DE)||€87.60||-2.49|
|Biogen Inc (BIIB.OQ)||$229.02||-9.60|
Earnings vs. Estimates
Analyst Research Reports
StemCells Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Provider : Thomson Reuters Stock Report
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.